European Journal of Molecular & Clinical Medicine

Aim: To study the correlation between IL6 and hsCRP (High sensitive C-reactive Protein) with Ischaemic stroke in patients on Antidiabetic therapy.
Materials and Methods: We recruited 200 participants with Ischaemic stroke from both outpatient and in-patient. In this study patients were divided into two groups. Group A Ischaemic stroke with DM and group B withIschaemic stroke but without DM.Blood was drawn with minimally traumatic venipuncture for measurement of serum inflammatory markers. Blood was centrifuged by 3,000 g for 15 min at 4 °C, and then aliquots were stored at -70 °C. Serum hs-CRP was measured by latex turbidimetric immunoassay with a sensitivity of 0.01 mg/L. Serum IL-6 were measured by enzyme-linked immunosorbent assay. With a sensitivity of 0.01 pg/mL. The detectable limit for Serum IL-6 was 0.01 pg/mL.
Results: There were significant differences in the traditional risk factors such as age, the prevalence of hypertension, coronary heart disease, silent lacunar infarction (SLI) and WMLs. MoCA Scores or the using rate of antithrombotic drugs between the group 1and group 2. (P < 0.05). Similarly, there were significant differences such as age, or the prevalence of alcohol intake, SLI and WML between the DM and NON-DM group (P < 0.05).We observed that serum hs-CRP and IL-6 levels (median: 7.94, and 9.34, respectively) in the group1 were higher than in those (median: 4.31 and 6.68,) without DM group 2.Logistic regression analysis showed that after adjustment for age, sex, BMI, smoking, alcohol intake, hypertension, diabetes, hyperlipidemia, coronary heart disease, the use of antithrombotic drugs and the presence of SLI and WML, inflammatory marker level remained to be associated with DM. The adjusted ORs of hs-CRP and IL-6 were 1.98 (1.55-2.42) and 1.56 (1.33-1.86) in group 1 and 2.58 (1.79-3.36) and1.69 (1.22-2.57) in group 2.